(UroToday.com) The 2025 ASTRO annual meeting featured a predictive markers in prostate cancer session and a presentation by Dr. Melvin L. K. Chua discussing validation of a prognostic multimodal ...
In intermediate risk prostate cancer patients randomized to short-term ADT and either 70 Gy or 76 Gy, testosterone recovery to normal level is associated with a significant improvement in overall ...
The investigators hypothesized that the use of proton therapy for extended lymph node irradiation of the pelvic and ...
The presence of adverse molecular features most closely correlated with genomic classifier scores, even within low grade tumors. There was an observed nearly 20-fold increase in the presence of ...
Primary physician reporting grade 2+ toxicity per CTCAE version 5.0 was the primary endpoint. Follow-up was performed 30 days post-treatment and subsequently every 3 to 4 months for 2 years: ...
The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...
Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in ...
A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a ...
The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...
Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...
ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy ...
No patients died of prostate cancer. The 5-year overall survival was 90%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback